Trial record 1 of 1 for:    Breast BRE09-146
Previous Study | Return to List | Next Study

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

This study is ongoing, but not recruiting participants.
Clovis Oncology, Inc.
Information provided by (Responsible Party):
Hoosier Cancer Research Network Identifier:
First received: February 23, 2010
Last updated: September 11, 2015
Last verified: September 2015
No Study Results Posted on for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: July 2016
  Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Miller K, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, Silverman P, King MC, Badve SS, Perkins SM. Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier Oncology Group BRE09-146. J Clin Oncol 33:5s, 2015 (suppl; abstr 1082)